Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models.
OBJECTIVE
The cell adhesion molecule integrin α(v)β(3) is an important player in the process of tumor angiogenesis and metastasis. Abegrin™, a fully humanized anti-integrin α(v)β(3) monoclonal antibody, was currently in clinical trials for cancer therapy. Herein, we labeled Abegrin™ with (111)In, evaluated the in vitro and in vivo characteristics, and investigated whether the expression of integrin α(v)β(3) in tumors could be imaged with (111)In-labeled Abegrin™.


METHODS
The binding affinity and specificity of Abegrin™ was analyzed using U87MG glioblastoma cells. Abegrin™ was coupled with 1,4,7,10-tetraazadodecane-N,N',N",N'″-tetraacetic acid (DOTA) for (111)In radiolabeling. γ Imaging of (111)In-DOTA-Abegrin™ was carried out in nude mice bearing both integrin α(v)β(3)-positive U87MG and integrin α(v)β(3)-negative HT-29 tumors. Biodistribution and blocking studies of (111)In-DOTA-Abegrin™ were investigated in U87MG tumor-bearing nude mice.


RESULTS
Abegrin™ exhibited high-binding affinity to human integrin α(v)β(3) expressed on U87MG cells (K (d) of 0.35 ± 0.06 nM). The antibody retained antigen-binding affinity/specificity after DOTA conjugation. γ Imaging showed that the tumor uptake of (111)In-DOTA-Abegrin™ in integrin α(v)β(3)-positive U87MG tumors was much higher than that in integrin α(v)β(3)-negative HT-29 tumors. In the HT-29 tumors, Abegrin™ was mainly nonspecifically accumulated around the blood vessels, while in the U87MG tumors, besides the nonspecific tumor retention, Abegrin™ also specifically bound the human integrin α(v)β(3) expressed on the tumor cells. Biodistribution and blocking studies exhibited that the U87MG tumor uptake of (111)In-DOTA-Abegrin™ decreased from 14.12 ± 0.44 to 6.93 ± 0.94 percentage of injected dose per gram of tissue after coinjection of excess dose of cold Abegrin™, which confirmed the in vivo integrin α(v)β(3) binding specificity of (111)In-DOTA-Abegrin™.


CONCLUSIONS
Abegrin™ showed specific binding to human integrin α(v)β(3) expressed on the tumor cells. (111)In-DOTA-Abegrin™ can specifically target the human integrin α(v)β(3) expression in the nude mouse model. (111)In-DOTA-Abegrin™ has a potential for clinical translation as an agent for integrin α(v)β(3)-positive tumor imaging, evaluating tumor angiogenic status and monitoring the therapeutic efficacy of Abegrin™-based cancer therapy.
Liu
Zhaofei
Z
Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China.
Jia
Bing
B
Zhao
Huiyun
H
Chen
Xiaoyuan
X
Wang
Fan
F
D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism* / Q000493:pharmacokinetics; D061067:Antibodies, Monoclonal, Humanized; D045744:Cell Line, Tumor; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007205:Indium Radioisotopes / Q000378:metabolism* / Q000493:pharmacokinetics; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D051379:Mice; D008819:Mice, Nude; D023421:Models, Animal; D014018:Tissue Distribution
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007205:Indium Radioisotopes; D039302:Integrin alphaVbeta3; C112567:etaracizumab
Bioconjug Chem. 2008 Jun;19(6):1170-8
18491928
Cancer Res. 2006 Oct 1;66(19):9673-81
17018625
Cancer Biother Radiopharm. 2001 Apr;16(2):125-32
11385959
J Nucl Med. 2009 Jul;50(7):1168-77
19525469
Clin Cancer Res. 2004 Dec 15;10(24):8674-82
15623652
Curr Oncol Rep. 2006 Mar;8(2):96-103
16507218
J Nucl Med. 2008 Nov;49(11):1809-12
18927323
N Engl J Med. 2001 Sep 27;345(13):995-6
11575295
Clin Cancer Res. 2008 Nov 15;14(22):7330-9
19010848
J Nucl Med. 2006 May;47(5):763-9
16644745
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6610-6
18006761
Drug Dev Res. 2008;69(6):329-339
20628538
J Nucl Med. 2009 Jan;50(1):123-31
19091906
Curr Drug Targets. 2003 Feb;4(2):123-31
12558065
Invest New Drugs. 2008 Feb;26(1):35-43
17876527
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6037-42
9600913
Int Immunopharmacol. 2003 Mar;3(3):319-28
12639809
J Clin Invest. 1999 May;103(9):1227-30
10225964
J Nucl Med. 2009 Jan;50(1):116-22
19091899
Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):81-93
18712381
Science. 1999 Aug 13;285(5430):1028-32
10446041
Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1557-61
1371877
Curr Cancer Drug Targets. 2006 Mar;6(2):89-105
16529540
J Med Chem. 2009 Jan 22;52(2):425-32
19113865
Biochem Biophys Res Commun. 2006 Oct 20;349(2):816-24
16950201
Clin Cancer Res. 2000 Aug;6(8):3056-61
10955784
Eur J Cancer. 2008 Sep;44(13):1835-40
18632262
Science. 1994 Apr 22;264(5158):569-71
7512751
Adv Enzyme Regul. 2001;41:189-207
11384745
Cancer Biother Radiopharm. 2009 Feb;24(1):15-24
19216631
Eur J Nucl Med Mol Imaging. 2009 Jun;36(6):947-57
19159928
Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12462-7
17626788
Cancer Res. 2008 Dec 1;68(23):9746-53
19047153
J Nucl Med. 2008 Jul;49(7):1066-74
18552139
Cell. 1992 Apr 3;69(1):11-25
1555235
Anticancer Agents Med Chem. 2006 Sep;6(5):407-28
17017851
Neuroreport. 2008 Jul 2;19(10):1009-14
18580570
J Med Chem. 2004 Mar 11;47(6):1465-74
14998334
J Neuropathol Exp Neurol. 1996 Nov;55(11):1143-9
8939197